Blood sample study explores new target for inflammatory arthritis
NCT ID NCT03322618
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at blood samples from 24 people with axial spondyloarthritis (a type of inflammatory arthritis) and 12 healthy volunteers to understand how a receptor called KIR3DL2 contributes to inflammation. Researchers also tested whether a drug called IPH4102 could reduce inflammation in the lab. No treatments were given to participants, so there was no direct benefit from taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS (AS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique Hopitaux de Marseille
Marseille, 13354, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new criteria better spot a spine disease that mimics back pain?
- Digital diary aims to decode painful flares in spine condition
- Could a common arthritis drug tame recurring eye inflammation?
- New app aims to ease depression and pain in ankylosing spondylitis patients
- Nerve block injection may ease back pain in ankylosing spondylitis patients
- Smartphone addiction may worsen neck problems in arthritis patients